Nobuhiro Kanaji
Overview
Explore the profile of Nobuhiro Kanaji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanaji N, Misaki N, Murota M, Iwata M, Ishikawa R, Yamamura K, et al.
BMC Pulm Med
. 2024 Dec;
24(1):610.
PMID: 39695614
Background: Despite the autoimmune nature of psoriasis, the potential association between psoriasis and interstitial lung disease (ILD) remains underexplored. This study aimed to investigate the frequency and clinical features of...
2.
Kanaji N, Yokohira M, Inoue T, Watanabe N, Mizoguchi H, Komori Y, et al.
Transl Lung Cancer Res
. 2024 Oct;
13(9):2340-2351.
PMID: 39430339
Background: Lung cancer was often diagnosed by malignant pleural effusion (MPE). Excessive MPE is generally discarded. The establishment of cell lines and the generation of cancer mouse models have the...
3.
Masuda T, Tsubata Y, Hata K, Horie M, Kiura K, Kanaji N, et al.
Thorac Cancer
. 2024 Oct;
15(34):2408-2417.
PMID: 39415454
Introduction: Studies have shown the antitumor efficacy of immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). However, it is unclear whether the...
4.
Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, et al.
JTO Clin Res Rep
. 2024 May;
5(4):100655.
PMID: 38706978
Introduction: Immune checkpoint inhibitor (ICI)-based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in...
5.
Norikane T, Ishimura M, Mitamura K, Yamamoto Y, Arai-Okuda H, Manabe Y, et al.
J Clin Med
. 2024 Mar;
13(6).
PMID: 38541851
Identifying programmed death-ligand-1 (PD-L1) expression is crucial for optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of intratumoral metabolic heterogeneity specifically derived from F-fluorodeoxyglucose (FDG) positron emission tomography...
6.
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, et al.
J Cancer Res Clin Oncol
. 2024 Feb;
150(2):89.
PMID: 38347279
Purpose: Immune checkpoint inhibitors (ICIs) are ineffective against epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics of patients who were...
7.
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, et al.
Lung
. 2024 Jan;
202(1):63-72.
PMID: 38265672
Purpose: This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD). Methods: This multicenter retrospective...
8.
Kanaji N, Watanabe N, Inoue T, Mizoguchi H, Sakamoto K, Komori Y, et al.
J Med Case Rep
. 2023 Dec;
17(1):497.
PMID: 38037127
Background: Superior vena cava syndrome is rarely attributed to chronic obstructive pulmonary disease. Case Presentation: We present the case of an 82-year-old Japanese man who experienced gradually progressive dyspnea on...
9.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, et al.
Lung Cancer
. 2023 Aug;
184:107349.
PMID: 37651927
Background: Adding bevacizumab to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) prolonged the progression-free survival (PFS), but limited data are available for second-generation EGFR-TKIs. AfaBev-CS is a randomized,...
10.
Matsumoto K, Kakazu N, Imataki O, Kondo A, Kanaji N, Kadowaki N
Br J Haematol
. 2023 Jul;
202(6):e67-e70.
PMID: 37433466
No abstract available.